These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 29323548

  • 1. 18F-Fluorocholine PET Whole-Body MRI in the Staging of High-Risk Prostate Cancer.
    Metser U, Berlin A, Halankar J, Murphy G, Jhaveri KS, Ghai S, Tau N.
    AJR Am J Roentgenol; 2018 Mar; 210(3):635-640. PubMed ID: 29323548
    [Abstract] [Full Text] [Related]

  • 2. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
    Poulsen MH, Bouchelouche K, Høilund-Carlsen PF, Petersen H, Gerke O, Steffansen SI, Marcussen N, Svolgaard N, Vach W, Geertsen U, Walter S.
    BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
    [Abstract] [Full Text] [Related]

  • 3. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
    Evangelista L, Cimitan M, Zattoni F, Guttilla A, Zattoni F, Saladini G.
    Scand J Urol; 2015 Dec; 49(5):345-53. PubMed ID: 25649494
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Comparison of MRI Sequences in Whole-Body PET/MRI for Staging of Patients With High-Risk Prostate Cancer.
    Metser U, Chan R, Veit-Haibach P, Ghai S, Tau N.
    AJR Am J Roentgenol; 2019 Feb; 212(2):377-381. PubMed ID: 30332285
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Recurrent prostate cancer after radical prostatectomy: restaging performance of 18F-choline hybrid PET/MRI.
    Achard V, Lamanna G, Denis A, De Perrot T, Mainta IC, Ratib O, Iselin C, Miralbell R, Garibotto V, Zilli T.
    Med Oncol; 2019 Jun 12; 36(8):67. PubMed ID: 31190232
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S, Coronado-Poggio M, García-Vicente AM, García-Garzón JR, Alonso-Farto JC, de la Jara AC, Maldonado-Suárez A, Rodríguez-Fernández A.
    BJU Int; 2015 Jun 12; 115(6):874-83. PubMed ID: 25307619
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Whole-body 18F-fluorocholine (FCH) PET/CT and MRI of the spine for monitoring patients with castration-resistant prostate cancer metastatic to bone: a pilot study.
    Balogova S, Zakoun JB, Michaud L, Khalil A, Tassart M, Esteso A, Kerrou K, Huchet V, Carette MF, Lotz JP, Talbot JN.
    Clin Nucl Med; 2014 Nov 12; 39(11):951-9. PubMed ID: 25140552
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.